91 related articles for article (PubMed ID: 12577246)
1. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
2. Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.
Varghese JJ; Schmale IL; Mickelsen D; Hansen ME; Newlands SD; Benoit DSW; Korshunov VA; Ovitt CE
J Dent Res; 2018 Oct; 97(11):1252-1259. PubMed ID: 29634396
[TBL] [Abstract][Full Text] [Related]
3. Advances of Amifostine in Radiation Protection: Administration and Delivery.
Ji L; Cui P; Zhou S; Qiu L; Huang H; Wang C; Wang J
Mol Pharm; 2023 Nov; 20(11):5383-5395. PubMed ID: 37747899
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide in European and North American men participating in the AFFIRM trial.
Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG; Marshall A; Dunn JA; Middleton MR; Nathan PD; Gore M; Davidson N; Nicholson S; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Young G; Lorigan P
Lancet Oncol; 2014 May; 15(6):620-30. PubMed ID: 24745696
[TBL] [Abstract][Full Text] [Related]
8. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).
Gerber B; von Minckwitz G; Eidtmann H; Rezai M; Fasching P; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Loibl S; Untch M
Ann Surg Oncol; 2014 Aug; 21(8):2517-24. PubMed ID: 24740826
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; de Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E
J Clin Oncol; 2014 May; 32(13):1309-16. PubMed ID: 24687829
[TBL] [Abstract][Full Text] [Related]
10. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Rugo HS; Pritchard KI; Gnant M; Noguchi S; Piccart M; Hortobagyi G; Baselga J; Perez A; Geberth M; Csoszi T; Chouinard E; Srimuninnimit V; Puttawibul P; Eakle J; Feng W; Bauly H; El-Hashimy M; Taran T; Burris HA
Ann Oncol; 2014 Apr; 25(4):808-815. PubMed ID: 24615500
[TBL] [Abstract][Full Text] [Related]
11. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Kaufman HL; Kirkwood JM; Hodi FS; Agarwala S; Amatruda T; Bines SD; Clark JI; Curti B; Ernstoff MS; Gajewski T; Gonzalez R; Hyde LJ; Lawson D; Lotze M; Lutzky J; Margolin K; McDermott DF; Morton D; Pavlick A; Richards JM; Sharfman W; Sondak VK; Sosman J; Steel S; Tarhini A; Thompson JA; Titze J; Urba W; White R; Atkins MB
Nat Rev Clin Oncol; 2013 Oct; 10(10):588-98. PubMed ID: 23982524
[TBL] [Abstract][Full Text] [Related]
12. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Blanchard P; Bourhis J; Lacas B; Posner MR; Vermorken JB; Cruz Hernandez JJ; Bourredjem A; Calais G; Paccagnella A; Hitt R; Pignon JP;
J Clin Oncol; 2013 Aug; 31(23):2854-60. PubMed ID: 23835714
[TBL] [Abstract][Full Text] [Related]
13. Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder.
Otto W; May M; Fritsche HM; Dragun D; Aziz A; Gierth M; Trojan L; Herrmann E; Moritz R; Ellinger J; Tilki D; Buchner A; Höfner T; Brookman-May S; Nuhn P; Gilfrich C; Roigas J; Zacharias M; Denzinger S; Hohenfellner M; Haferkamp A; Müller SC; Kocot A; Riedmiller H; Wieland WF; Stief CG; Bastian PJ; Burger M
Gend Med; 2012 Dec; 9(6):481-9. PubMed ID: 23217567
[TBL] [Abstract][Full Text] [Related]
14. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.
May M; Herrmann E; Bolenz C; Tiemann A; Brookman-May S; Fritsche HM; Burger M; Buchner A; Gratzke C; Wülfing C; Trojan L; Ellinger J; Tilki D; Gilfrich C; Höfner T; Roigas J; Zacharias M; Gunia S; Wieland WF; Hohenfellner M; Michel MS; Haferkamp A; Müller SC; Stief CG; Bastian PJ
Eur Urol; 2011 May; 59(5):712-8. PubMed ID: 21296488
[TBL] [Abstract][Full Text] [Related]
15. Development and external validation of an extended 10-core biopsy nomogram.
Chun FK; Briganti A; Graefen M; Montorsi F; Porter C; Scattoni V; Gallina A; Walz J; Haese A; Steuber T; Erbersdobler A; Schlomm T; Ahyai SA; Currlin E; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
Eur Urol; 2007 Aug; 52(2):436-44. PubMed ID: 17010505
[TBL] [Abstract][Full Text] [Related]
16. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
Bernier J; Domenge C; Ozsahin M; Matuszewska K; Lefèbvre JL; Greiner RH; Giralt J; Maingon P; Rolland F; Bolla M; Cognetti F; Bourhis J; Kirkpatrick A; van Glabbeke M;
N Engl J Med; 2004 May; 350(19):1945-52. PubMed ID: 15128894
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
Riley P; Glenny AM; Hua F; Worthington HV
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012744. PubMed ID: 28759701
[TBL] [Abstract][Full Text] [Related]
18. Radiation-Induced Oral Mucositis.
Maria OM; Eliopoulos N; Muanza T
Front Oncol; 2017; 7():89. PubMed ID: 28589080
[TBL] [Abstract][Full Text] [Related]
19. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.
Jin JF; Zhu LL; Chen M; Xu HM; Wang HF; Feng XQ; Zhu XP; Zhou Q
Patient Prefer Adherence; 2015; 9():923-42. PubMed ID: 26170642
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of amifostine in elderly cancer patients.
Barutca S; Meydan N; Akar H; Yavasoglu I; Kadikoylu G; Bolaman Z
Curr Ther Res Clin Exp; 2004 Jan; 65(1):113-24. PubMed ID: 24936110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
